Desperation showing again. I wonder if somehow wor
Post# of 72447
(Total Views: 266)
Posted On: 01/12/2017 9:50:12 PM
Desperation showing again. I wonder if somehow word has leaked out from a clinical trial, or maybe someone at a big pharma has disclosed information that they learned after signing a Non-Disclosure Agreement which was supposed to prevent info leakage.
Because the load of BS has gotten surprisingly high.
Anyone who thinks that a market cap of about 150 million is too high for a company with 5 clinical trials, involving 3 different drugs, for 5 different applications -- well, clearly that person is either very ignorant, or has an ulterior motive. Does anyone really think that that a company trying to find a better drug for h. pylori (the cause of stomach ulcers, which are already treatable with a cocktail of existing antibiotics) and Crohn's Disease (an unmet need -- but not an extremely common disease) should be valued more than CTIX, with its 5 clinical trials and 3 completely different drugs -- those clinical trials being for much more common diseases or treatment of a debilitating side effect of cancer treatment (Brilacidin-Oral Mucositis)?
Nonsensical comparisons and claims that CTIX is overvalued should be seen as what they are -- desperate acts of people who want to suppress the stock price. Whatever their reasons, it really is a waste of time and their employers' resources to keep posting nonsense here. Surely even the newest readers must recognize the foolishness of these attempts to bash the stock.
Because the load of BS has gotten surprisingly high.
Anyone who thinks that a market cap of about 150 million is too high for a company with 5 clinical trials, involving 3 different drugs, for 5 different applications -- well, clearly that person is either very ignorant, or has an ulterior motive. Does anyone really think that that a company trying to find a better drug for h. pylori (the cause of stomach ulcers, which are already treatable with a cocktail of existing antibiotics) and Crohn's Disease (an unmet need -- but not an extremely common disease) should be valued more than CTIX, with its 5 clinical trials and 3 completely different drugs -- those clinical trials being for much more common diseases or treatment of a debilitating side effect of cancer treatment (Brilacidin-Oral Mucositis)?
Nonsensical comparisons and claims that CTIX is overvalued should be seen as what they are -- desperate acts of people who want to suppress the stock price. Whatever their reasons, it really is a waste of time and their employers' resources to keep posting nonsense here. Surely even the newest readers must recognize the foolishness of these attempts to bash the stock.
(1)
(0)